PBSV Research | Milton Maxwell

PBSV

Pharma-Bio Serv, Inc.

0.5500

+0.0000+0%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

12.61M

P/E (TTM)

Basic EPS (TTM)

0.00

Dividend Yield

Recent Filings

10-K

FY2025 results

1/29/26Jan 29, 2026

Pharma-Bio Serv posted FY2025 revenue of $9.0M, down 5.5% y/y from $9.5M, yet gross profit jumped to 32.3% from 26.5% thanks to margin gains in Puerto Rico and US plus a high-margin European project that soared $1.2M. Europe revenue hit 19.2% of total, up sharply, while Puerto Rico (51.5%) and US (29.1%) slipped. SG&A fell $0.3M; other income held at $0.5M, trimming net loss to $0.1M ($0.004/share). Q4 saw aggressive buybacks of 14,450 shares at $0.64 average. Working capital stood at $11.6M. Three clients drove 43.5% of revenue. Client concentration threatens momentum.

8-K

Revenues dip, loss narrows, dividend

1/29/26Jan 29, 2026

Pharma-Bio Serv reported full-year revenues of approximately $9.0 million for the period ended October 31, 2025, down $0.5 million from prior year, yet narrowed its net loss to $0.1 million, up $0.7 million. Board approved a $0.075 per share special dividend, payable March 20, 2026 to holders of record February 27. Portfolio rationalization sharpened focus on Latin America and Europe. Losses narrowed sharply.

10-Q

Q3 FY2025 results

9/15/25Sep 15, 2025

Pharma-Bio Serv posted Q3 FY2025 revenue of $2.0M, down 18.8% y/y from $2.4M yet lifting gross margin to 29.3% from 26.3% on better Puerto Rico and US mixes despite Europe drop. Operating loss narrowed to $314K from $382K y/y, trimming SG&A 12.7%; net loss hit $204K or $(0.009) per diluted share on 22.9M shares, consistent with calculation. Europe revenue soared YTD to $1.4M from $360K while Puerto Rico fell 19%. Cash sits at $4.0M with $6.8M marketable securities; no debt. Steady cash burn. Customer concentration runs high.

8-K

Q3 revenues dip, losses shrink

9/15/25Sep 15, 2025

Pharma-Bio Serv reported Q3 revenues of $2.0M, down from $2.4M last year, with nine-month revenues at $6.9M versus $7.2M. Net loss narrowed to $0.2M and $0.1M, respectively, improving $0.1M and $0.7M year-over-year. Cost streamlining boosts agility. Momentum builds for big projects.

8-K

Q2 revenues rise to $2.4M

6/16/25Jun 16, 2025

Pharma-Bio Serv reported Q2 revenues of $2.4M, up from $2.3M last year, with six-month sales at $4.9M versus $4.8M. Net income hit $0.1M for both periods, boosting earnings $0.3M and $0.6M over prior year. High-margin projects drive results. CEO eyes future growth amid risks.

About

Pharma-Bio Serv, Inc. operates as a regulatory affairs, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services, including regulatory compliance, validation, technology transfer, engineering, project management, and process support services. It serves pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.

CEO

Mr. Victor Sanchez

IPO

5/7/2007

Website

https://www.pbsvinc.com

Employees

Sector

Healthcare

Industry

Health Information Services